NAP (5mg)

What is NAP (Davunetide)?

NAP (NAPVSIPQ) is the active fragment of activity-dependent neuroprotective protein (ADNP) — a key regulator of microtubule stability and synaptic integrity.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

NAP is the eight-amino-acid neuroprotective core of ADNP. It binds tubulin and stabilizes microtubules, supports axonal transport, and reduces tau hyperphosphorylation. NAP enhances autophagy and synaptic protein expression in models of neurodegeneration.

What are the research questions?

• Tauopathy research: Reduced tau pathology in transgenic Alzheimer's and PSP models.
• Schizophrenia cognitive symptoms: Phase 2 trials reported improvement in functional capacity (UCSD Performance-Based Skills Assessment).
• ADNP syndrome: Direct mechanistic target in this rare neurodevelopmental disorder.

What does the published work describe?

Gozes I et al. (J Pharmacol Exp Ther 2009) — neuroprotection across multiple models. Morimoto BH et al. (Curr Alzheimer Res 2013) — memory improvement in amnestic MCI. Phase 3 in PSP did not meet primary endpoint, narrowing development focus.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Gozes I et al. J Pharmacol Exp Ther 2009
2. Morimoto BH et al. Curr Alzheimer Res 2013

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is NAP (Davunetide) handled in the lab?

Plan a NAP (Davunetide) stock solution from the sequence, the listed molecular weight (824.86 g/mol) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave